Prescribing Habits for Androgenetic Alopecia Among Dermatologists in Spain in 2024: A Cross-Sectional Study

The management of androgenetic alopecia (AGA) is evolving. This study updates current prescribing practices compared with 2019-2020. A digital survey was conducted among dermatologists in Spain between March and June 2024, focusing on AGA treatment trends, nutricosmetic product selection, and the adoption of hair skinification. A total of 202 dermatologists participated, including 164 attending physicians and 38 residents. AGA remained the most frequent cause of alopecia consultation (51%). Oral minoxidil was the most prescribed treatment for male AGA (89.1%), premenopausal female AGA (92.1%), and postmenopausal female AGA (93.1%). There has been a shift toward oral minoxidil and a decline in topical formulations. Oral dutasteride has now replaced finasteride as the most widely prescribed antiandrogen for male AGA, reflecting its growing acceptance despite off-label use. For premenopausal AGA, spironolactone is now the most frequently chosen antiandrogen, surpassing oral contraceptives and finasteride. Meanwhile, dutasteride has become the predominant antiandrogen for postmenopausal AGA, replacing finasteride.